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Abstract
Background
People with dementia are susceptible to adverse drug reactions (ADRs). However, they are
not always closely monitored for potential problems relating to their medicines: structured
nurse-led ADR Profiles have the potential to address this care gap. We aimed to assess the
number and nature of clinical problems identified and addressed and changes in prescribing
following introduction of nurse-led medicines’monitoring.
Design
Pragmatic cohort stepped-wedge cluster Randomised Controlled Trial (RCT) of structured
nurse-led medicines’monitoring versus usual care.
Setting
Five UK private sector care homes
Participants
41 service users, taking at least one antipsychotic, antidepressant or anti-epileptic
medicine.
Intervention
Nurses completed the West Wales ADR (WWADR) Profile for Mental Health Medicines with
each participant according to trial step.
Outcomes
Problems addressed and changes in medicines prescribed.
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Data Collection and Analysis
Information was collected from participants’ notes before randomisation and after each of
five monthly trial steps. The impact of the Profile on problems found, actions taken and
reduction in mental health medicines was explored in multivariate analyses, accounting for
data collection step and site.
Results
Five of 10 sites and 43 of 49 service users approached participated. Profile administration
increased the number of problems addressed from a mean of 6.02 [SD 2.92] to 9.86 [4.48],
effect size 3.84, 95% CI 2.57–4.11, P <0.001. For example, pain was more likely to be
treated (adjusted Odds Ratio [aOR] 3.84, 1.78–8.30), and more patients attended dentists
and opticians (aOR 52.76 [11.80–235.90] and 5.12 [1.45–18.03] respectively). Profile use
was associated with reduction in mental health medicines (aOR 4.45, 1.15–17.22).
Conclusion
TheWWADR Profile for Mental Health Medicines can improve the quality and safety of
care, and warrants further investigation as a strategy to mitigate the known adverse effects
of prescribed medicines.
Trial Registration
ISRCTN 48133332
Introduction
The adverse effects of prescribed medicines are a public health problem, in the UK[1–4], and
worldwide[5,6]. Adverse drug reactions (ADRs)7 are responsible for: 20.8% (60/290) of pre-
ventable emergency re-admissions within one year of discharge[8]; 4–6% of UK hospital bed
occupancy[9]; 10% (68/678) hospitalisations in US Veterans’ Affairs Medical Centres[10];
3.7% hospital admissions globally[11]; an increasing number of UK hospital admissions[12];
£1–2.5bn NHS costs annually[13] and ~$30bn expenditure each year in the USA[14].
Although preventable ADRs account for 5–8% of all hospital admissions[15], adverse conse-
quences of untreated conditions are equally common in primary care[16]. Enhanced patient
monitoring might prevent many of these problems[6,17–21], and our nurse-led intervention
has improved care in several clinical settings[22–25].
We focus on three key medicine groups: antipsychotics, anti-epileptics, and antidepressants,
which are often prescribed to people living with dementia, either for the management of associ-
ated behavioural and psychological symptoms or the frequently accompanying co-morbid con-
ditions of depression and epilepsy. However there are concerns relating to the use of these
medicines because of their side-effect profiles. Whether to manage symptoms of dementia or
co-morbidities, 25–50% of people with dementia receive antipsychotics[26–28]; one third of
care home residents receive antidepressants[29]; and 10–20% of people with Alzheimer’s dis-
ease require anti-epileptics[30]. Consequently, many older people, particularly those with
dementia, are vulnerable to the adverse effects of mental health medicines[31,24], as evidenced
by current prescribing trends[32]. The Protean ADRs attributed to mental health medicines
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include worsening cognitive impairment, aggression/ restlessness, sedation, falls, bleeding, and
changes in cardiovascular and gastro-intestinal function, as detailed on the WWADR Profile
[24] (S1 Appendix). There is particular concern over the use of antipsychotic medication in
people living with dementia, with only modest evidence to suggest clinical improvement but
increasing risk of adverse health outcomes and mortality[25].
Despite widespread acknowledgment of the ‘ADR problem’[33,34], no recommendations
on implementation of medicines’monitoring procedures are offered. While the UK’s National
Institute for Health and Care Excellence (NICE) [35] specify parameters for monitoring, nei-
ther they nor leading reviews[19] nor reports[3,4] offer monitoring strategies. Written infor-
mation, while not harmful, is not well regarded by service users, and on its own is insufficient
[36,37]. However, some primary care physicians undertake medication review only if offered
suitable financial incentives, including upfront payment of £350[38], and evidence from phar-
macist-led interventions is equivocal[39] and described as ‘low quality’[40,16] or uncertain
[19,41]. Accordingly, our West Wales ADR (WWADR) Profiles are designed to use an alterna-
tive link in the ‘medication chain’, and to be completed by nurses, who are usually the profes-
sionals with the most intimate knowledge of patients. The Profiles aim to minimize ADRs
without compromising the beneficial effects of medicines[22–25,42]–congruent with recent
‘calls to action’[2–4,43]—and promote guideline adherence[15,35]. However, the WWADR
Profile for Mental Health medicines has not been tested in clinical trials
We aimed to assess 1) clinical impact 2) potential cost impact and 3) any harms of nurse-
led medicines’monitoring using the WWADR Profile for Mental Health Medicines[24,42].
Our objectives were to test whether, at individual participant level, introduction of the Profile
affected: the number and nature of problems identified and addressed; prescribing; dementia
severity; potential service costs and harms.
Methods
Design
In this cohort stepped wedge cluster randomised trial (SW-CRT), five sites (care homes) were
randomised to five sequential steps or time points. There were equal numbers of observations
with and without the Profile over the six months of the trial. The cohort SW-CRT design
strengthens the traditional cluster randomised controlled trial (RCT): all participants receive
the intervention, reducing ‘resentful demoralisation’; at each step, sites who receive the inter-
vention act as cross-sectional controls for those who had not; each participant acts as their own
longitudinal control, allowing ‘before and after’ comparison[44,45]; and institution level adop-
tion of the Profile simulates a policy-level intervention. Because all participants cross-over to
the intervention by the end of the trial, cohort SW-CRTs are recommended for testing patient
safety interventions[46], likely to be beneficial[47], and unlikely to cause harm. (The CON-
SORT checklist is appended [S1 CONSORT Checklist]) [48]. The authors confirm that all
ongoing and related trials for this intervention are registered (ISRCTN 48133332). Prior to par-
ticipant recruitment in May, we recruited and trained the nurses involved in the project.
The SWWales NHS Research Ethics committee (REC) approved the study (reference: 13/
WA/0067, 10th April 2013). The protocol is available (S1 Protocol).
Participants. Recruitment and follow-up of participants was undertaken May to October
2013 in five sites with 181 service users. The sites were dispersed across South West Wales and
run by different private sector organisations. In all sites, prescription and administration of all
medicines were documented on paper-based medicines’ administration record (MAR) charts,
which were the responsibility of qualified nurses. Prescriptions were issued by primary care
practitioners and consultant-led secondary care services. Medicines were dispensed by
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community pharmacists in original packaging. Each site had its own record keeping format.
Patient records, including medication administration records, were regularly inspected to
ensure they met the standards of the Care and Social Services Inspectorate Wales (CSSIW). In
care homes, medication records include preparations for minor ailments, which are normally
purchased by ambulatory service users, and not necessarily recorded.
Individual participants’ inclusion criteria were: resident at the site; currently taking antipsy-
chotics and/or anti-epileptics and/or antidepressants; willing and able to give informed, signed
consent themselves, or where capacity was lacking, a guardian or consultee was willing to give
informed, verbal assent to review of documentation. We excluded those: aged<18 years; not
well enough to participate, according to the clinical judgement of their nurses.
Intervention. TheWest Wales ADR Profile for Mental Health Medicines[24] was intro-
duced into the five sites at staggered monthly intervals or steps, for completion with all eligible
participants. Once the Profile and guidelines had been introduced, and nurses trained (by SJ,
MG), nurses were asked to re-administer it every step as part of usual care. From previous
work[24], we anticipated that Profile completion would take 15–25 minutes.
The Profile aims to: alleviate under-reporting of adverse effects of prescribed medicines,
facilitate shared decision-making with service users and within the multi-disciplinary team
[15,49], and identify problems that merit attention irrespective of aetiology. The Profile con-
tains a structured template of 82 items to be completed over several interviews, if needed[24],
with comprehensive guidelines[42], to ensure unified recording of all information pertinent to
potential adverse effects of medicines commonly prescribed for mental health conditions
[24,42] (S1 and S2 Appendix). The profile was developed for administration during routine
nursing care[24,42,50–52], incorporating ADRs documented in formularies[34,53], and manu-
facturers’ literature. Inter-rater reliability for the items’ kappa values ranged 0.44–1.00, with
observational items generally having lower values[42].
Outcomes. The primary outcome was the number and nature of problems found and
addressed, described under ‘clinical impact’ in ‘data collection’, below. Secondary outcomes
were changes in individual problems, prescribing, disease severity, and potential costs and
harms of the intervention.
Sample size. In our feasibility before and after study[24] a mean of 3.0 [SD 5.4] more
problems were addressed following administration of the Profile, and the intra-cluster correla-
tion coefficient (ICC) was close to zero. To investigate whether this improvement would be
replicated in a larger sample would require a total sample of 28, with 80% power, 5% alpha,
two sided[54]. With 10 participants in each cluster, an ICC of 0.05, and a design effect of 1.45,
we calculated that 41 participants were needed[55]. We planned to recruit 50 participants from
5 sites, and anticipated 10% loss to follow up over 6 months.
Recruitment. Ten sites (care homes) were approached by the research team. Sites were
identified from the list of those working with the University, and telephoned for an appoint-
ment to explain the study and request participation pre-randomisation. All service users in par-
ticipating sites were assessed for eligibility and those meeting the inclusion criteria were
approached by their nurses.
Randomisation. The five sites were randomised by the Swansea Clinical Trials Unit
(SCTU) to determine at which of the five steps the Profile would be introduced in each site.
Sites were informed one month before introduction of the intervention.
Data Collection. Participants’ records were reviewed pre-intervention and at each of 5
subsequent data collection steps. One month between each step minimised the impact of
delayed treatment effects on study power[56]. We (MEG, SJ, LN, SS) extracted data from par-
ticipants’ case notes to identify compliance with the intervention and obtain information on
trial outcomes and objectives:
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1. Clinical impact was measured by:
a. Total number of problems documented as present and addressed at each data collection
step (primary outcome), as interval variables. The presence or absence of each possible
ADR and whether it was addressed were noted as binary variables (S1 Appendix).
b. The nature of specific benefits of the intervention, including: actions taken to reduce
ADRs listed on the Profile (S1 Appendix), such as monitoring vital signs, intake and
medicines’ administration[3,4], and pain management, based on previous work[24] Pain
is particularly important, as effective pain management improves the treatment of beha-
vioural difficulties and agitation in people with dementia in care homes[57]. Dementia,
sedation, antipsychotics and antidepressants are also important risk factors for falls and
injuries[30,34,58,59,60,61,62]. Case reports are included to capture the burden, severity
or nature of the problems. The presence or absence of each problem and actions taken to
address the problem were captured as binary variables, and the proportion of participant
records where these were documented was calculated with participants and steps as the
denominator (total 249). Case reports are included to capture the burden, severity and
nature of the problems.
c. Changes in prescription regimens as documented in administration records and referral
letters. Numbers, names and doses of medicines prescribed were recorded, and binary vari-
ables ‘any change in regimen’ and ‘reduction of medicines associated with mental health’
(antipsychotics, antidepressants, anitepileptics, benzodiazepines and antimuscarinics pre-
scribed to manage the adverse effects of antipsychotics) were calculated at each step.
d. Measures of dementia and illness severity: the Bristol Activities of Daily Living (ADL)
[63] scale for functional ability and MOUSEPAD[64] for psychopathology, as total scores
recorded by nurses at every data collection step, and treated as interval variables. Increas-
ing scores indicated increased dependency / dementia severity.
2. Estimated potential economic costs of delivering the intervention
3. Evidence that the Profile had harmed or burdened participants as captured in participants’
records, including adverse event forms, and reports from care providers.
Analysis. Data were entered into SPSS (version 20, IBM Corp. in Armonk, NY) for main
analyses and into R (R Foundation for Statistical Computing, Vienna, Austria) for confirma-
tory analyses. Problems addressed were listed. Analysis was based on participant level data,
clustered within sites. Outcome variables were analysed using generalized linear mixed effects
models with an indicator of profile use, baseline data on age, number of medicines prescribed,
prescription of antipsychotics, antiepileptics, antidepressants and SSRIs, (detailed in Table 1),
and data collection step considered as fixed explanatory variables. We considered separate
models for each variable of interest. We used normal models for interval variables and binary
logistic regression models for binary data. In each model, site was entered as a random effect
variable; this formally accommodated the observed ICCs in our data. The effect of the interven-
tion is reported as adjusted mean differences (β for interval variables) or adjusted odds ratios
(aOR for binary variables) taken from models which retain statistically significant covariates
and factors from the list above. Inferential statistics were confined to composite outcomes
(numbers of problem found and addressed, changes in prescribing, measures of illness severity)
and examples of the nature of the problems addressed selected for clinical importance (pain,
falls, sedation).
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Some problems could not be addressed within the month between data collection steps,
most particularly visits to opticians and dentists, where NHS access can take several weeks. To
account for the delayed effects of treatment, we analysed data on opticians’ and dentists’ visits
from first and last collection steps, thus effectively undertaking ‘before and after’ analyses of
numbers accessing these services within the last year; we retained all other aspects of the
modelling strategy, including a random effects variable for site. We undertook standard model
and residual diagnostics where appropriate; presentation of the analyses reflects joint decisions
by two authors. Case vignettes are presented for illustration.
Ethics
The study was explained to all potential participants and, where possible, their families, supple-
mented by written information, in English and Welsh. Residents’ or consultees’ consent for
researchers to review participants’ notes for information directly relevant to medicines’ use was
sought by qualified nurses, who were familiar with the Mental Capacity Act (2005)[65] and
employed by the site. Since this was a cluster RCT[66,67], and the research only involved
excerpting non-identifiable data from records, where the participant lacked capacity, the REC
considered it appropriate for qualified site staff to take verbal consent/ assent, witnessed by a
Table 1. Recruitment, Retention, Demographics and Prescription medicines at study entry.
Site 1 Site 2 Site 3 Site 4 Site 5 Full
sample
Recruitment
Number eligible 10 8 9 12 10 49
Number starting trial 10 8 5 10 10 43
Retention
Number completing 10 8 5 9 9 41
Demographics
Number female 3 3 5 7 7 25
Age: mean [SD] in years 72.60 [7.89] 69 [12.14] 87.40 [6.99] 85.90 [6.49] 81.00 [9.65] 78.7 [11.00]
Age: median [25th–75th centile] 71.5 [65.5–
80.75]
63 [60.25–
83.25]
88 [82–92.5] 87 [81–
91.25]
82.5 [71.5–
88.5]
80 [67–88]
Range (min-max) 63–84 58–88 76–95 75–96 66–94 58–96
Number registered for nursing care* 5 6 0 0 5 16
Prescribed medicines
Mean [SD] number of medicines**/ participant 6.8 [3.4] 11.1 [3.9] 9.6 [1.1] 9.1 [4.2] 10.6 [3.1] 9.3[3.7]
Median [25th–75th centile] number of medicines/
participant
6 [4–9.3] 10.5 [9–13.3] 10 [8.5–
10.5]
8 [6.5–11.8] 10.5 [7.5–13.5] 9 [7–11]
Range (min-max) 2–13 6–19 8–11 4–18 7–15 2–19
Number of participants prescribed:
Antipsychotics 5 5 3 6 2 21
Antidepressants (not SSRIs) 0 2 4 5 2 13
Antiepileptics 1 7 2 6 1 17
SSRIs 3 2 0 2 7 14
* Categorisation follows a needs assessment. Service users are assessed by NHS nurses and designated as needing nursing care or residential care.
Assessments are usually based on the Royal College of Nursing’s (2004) ‘Nursing assessment and Older People An RCN Toolkit’. London, RCN: http://
www.rcn.org.uk/__data/assets/pdf_ﬁle/0010/78616/002310.pdf
** Any combination preparations were counted as a single item. Enumerating the active ingredients of each product would have been impractical,
particularly for antacids and multivitamins.
doi:10.1371/journal.pone.0140203.t001
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signatory outside the research team[7:16,68:34]. Participants’ General Practitioners (GPs) were
informed of the project by letter. Usual standard care was delivered throughout. To cover the
time spent in recruiting participants and administering the measures of functioning and
dementia severity, sites received honoraria. Honoraria were not intended to cover administra-
tion of the Profile, as the questions posed were those that should be asked in routine care.
Findings
Five of 10 sites declined to participate; ‘pressure of work’ was the only explanation offered. Of
the 181 service users, 49 met inclusion criteria, and 43 consented to participate. In care home 5,
2 joined late. Nurses indicated that all participants lacked capacity to consent, and consent was
obtained from consultees. We retained 41 of the 43 service users: one died, and one did not
return from hospital, all before introduction of the Profile. Recruitment is summarized in Fig 1
and Table 1, and retention in Table 2.
At trial entry, 27/43 (62.8%) participants were receiving residential care, and 16 nursing
care; 25/43 (58.1%) were female. Participants’ ages ranged 58–96, mean 78.7 [SD 11.00],
median 80 [IQR 67–88].
Of the 43 participants, 39 had a recorded primary diagnosis of dementia (including alcohol-
related, vascular, Alzheimer’s, fronto-temporal), two were diagnosed with Korsakoff’s syn-
drome, and two with depression, but not dementia. A diagnosis of depression was recorded for
7 participants (five with co-morbid depression where primary diagnosis was dementia), and 27
were prescribed antidepressants. Prescribing patterns were not uniform in the 5 sites: more
participants were prescribed antiepileptics in site 2; site 5 used more SSRIs and fewer antipsy-
chotics (Table 1). Participants were prescribed between 2 and 19 medicines, (median 9 [7–11],
mean 9.3 [SD 3.7]), including treatments for physical health conditions.
Profile completion and all cross-over to Profile use was as scheduled. Laboratory test results
were often unavailable, as they were held by participants’ GPs. Monitoring of vital signs, food
and fluid intake and medicines’ administration increased on introduction of the Profile, and
was sustained at the close of the trial. Before Profile introduction, fluid and food intake and
medicines’ administration were monitored for ~50% participants; this rose to>95% of partici-
pants when all sites used the Profile. However, compliance with vital signs’monitoring was
incomplete, particularly for heart rhythm, girth and temperature (Table 2). Some nurses
Fig 1. Numbers in the analysis.
doi:10.1371/journal.pone.0140203.g001
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reported insufficient time to complete physiological measurements. Nine participants were
unable to stand, precluding measurement of standing BP.
1. Clinical impact
a. Problems found and addressed. More problems were found and actions taken when the
Profile was used (Tables 3 and 4). More problems were found than were addressed. Most prob-
lems were actioned more frequently with than without the Profile, particularly balance/ co-ordi-
nation, cognitive decline, violence, aggression, mood fluctuations, behaviour problems,
restlessness, confusion, apathy, hallucinations, sedation, headache, hearing problems, hypersaliva-
tion, emesis, missed meals, inadequate fluid intake, vision problems, pain andmissed medicines;
the exceptions were changes in weight, insomnia and bowel control. Typically, nurses modified
care plans and made referrals (Table 5). In some cases, problems such as incontinence, were long-
standing and considered intractable. The sharp and sustained increase in problem detection at
first use of the Profile in all sites (Table 3) was not reflected in actions taken to address problems
in all sites: in sites 2,4 and 5 the mean number of problems addressed more than doubled,
whereas little change was seen in site 1, and there was a slight decrease in site 3 (Table 4).
In adjusted analyses, more problems were found (adjusted mean difference 9.06 [95% CI
7.95–10.16]), and addressed (adjusted mean difference 3.34 [2.57–4.11]) when the Profile was
used. These increases were also associated with older age and higher number of prescription
medicines at baseline. Number of problems addressed varied with trial step, and was signifi-
cantly lower in steps 2–5, when Profile use and other factors were accounted (Table 6).
Table 2. Patient monitoring: number of participants with documentation of each problem. 2 participants joined late and 2 were lost to the study.
Step 1 baseline no Proﬁles n = 41 Step 6 all participants use Proﬁle
n = 41
Acceptable ranges* Problem n
(%)
No
problem n
(%)
Not
monitored n
(%)
Problem n
(%)
No
problem n
(%)
Not
monitored n
(%)
Vital signs
Heart rate 55–90bpm 0 28 (68.3) 13 (31.7) 2 (4.9) 30 (73.2) 9 (22.0)
Heart rhythm No irregularity 0 1 (2.4) 40 (97.6) 1 (2.4) 21 (51.2) 19 (46.3)
BP– 2 position for
postural
hypotension
Systolic drops <20mmHg or 10% on
standing
8 (19.5) 23 (56.1) 10 (24.4) 7 (17.1) 25 (61.0) 9 (22.0)
Weight Change of <2.4kg in 1 month 19 (46.3) 20 (48.8) 2 (4.9) 17 (41.5) 22 (53.7) 2 (4.9)
Girth <88cms in women, <102cms. in men 0 0 41 (100) 14 (34.1) 4 (9.6) 23 (56.1)
Temperature 36.8 ± 0.4°C 4 (9.6) 6 (14.6) 31 (75.6) 3 (7.3) 18 (43.9) 20 (48.8)
Oxygen saturation 97% 0 0 41 10 (24.4) 18 (43.9) 13 (31.7)
Intake
Fluids >1.2L + 1L taken within solid food 1 (2.4) 14 (34.1) 26 (63.4) 7 (17.1) 33 (80.5) 1 (2.4)
Missed meals 1 meal unﬁnished / day 6 (14.6) 17 (41.5) 18 (43.9) 14 (34.2) 25 (61) 2 (4.9)
Medicines’ administration
Missed doses <2 doses of prescribed medicines missed
over any period of 7 days in the last
month (including refusal)
1 (2.4) 5 (12.2) 35 (85.4) 6 (14.6) 35 (85.4) 0
Regular administration Regular medication taken at same time
each day
0 6 (14.6) 35 (85.4) 1 (2.4) 39 (95.1) 1 (2.4)
* Guidelines appended to the Proﬁle offered deﬁnitions of acceptable ranges of measurement and standards. Guidelines are available on request.
doi:10.1371/journal.pone.0140203.t002
Nurse-Led Medicines' Monitoring: A Stepped RCT
PLOSONE | DOI:10.1371/journal.pone.0140203 October 13, 2015 8 / 27
Table 4. Total number of problems addressed per participant at each step in each site. Bold text indicates roll-out of medicines’monitoring and Profile
administration 1 month before these data collection points (occasions when researchers extracted data from participants’ records). n = number of service
users in the site. One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised between steps 3 & 4. Participants
joined site 5 at steps 2 and 3. Problems explored are listed in Table 5 and on the Profile, S1 appendix. Fuller versions of these tables, including medians and
25th = 75th centiles are in S1 and S2 tables.
Total number of problems addressed
Site Step 1. Step 2. Step 3. Step 4. Step 5. Step 6.
5: n 8 9 10 9 9 9
Mean [SD] 4.25 [1.67] 4.89 [1.90] 5.30 [2.41] 5.00 [2.83] 4.40 [2.22] 10.70[4.97]
Full range 3–8 3–9 3–10 1–12 1–8 91–21
4: n 10 10 10 9 9 9
Mean [SD] 8.50 [3.44] 5.90 [2.47] 6.60 [2.27] 4.44 [2.24] 12.00 [4.61] 12.78 [4.68]
Full range 2–13 2–10 2–9 2–8 6–19 6–19
3: n 5 5 5 5 5 5
Mean [SD] 7.00 [2.92] 5.80 [1.92] 6.00 [4.18] 4.60 [1.34] 4.60 [1.52] 6.20 [2.17]
Full range 4–11 3–8 1–12 3–6 3–7 0–6
2: n 8 8 8 8 8 8
Mean [SD] 7.25 [3.37] 5.00 [3.12] 11.50 [4.38] 8.88 [4.61] 7.88 [5.17] 10.13 [5.19]
Full range 2–11 1–8 3–18 2–17 3–16 4–22
1: n 10 10 10 10 10 10
Mean [SD] 9.30 [2.63] 8.60 [2.99] 9.80 [3.62] 10.10 [3.41] 10.80 [4.57] 11.70[4.72]
Full range 5–13 5–14 3–14 4–16 3–18 4–20
doi:10.1371/journal.pone.0140203.t004
Table 3. Total number of problems found per participant at each step and in each site. Bold text indicates roll-out of medicines’monitoring and Profile
administration 1 month before these data collection points (occasions when researchers extracted data from participants’ records). n = number of service
users in the site. One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised between steps 3 & 4. Participants
joined site 5 at steps 2 and 3. Problems explored are listed in Table 5 and on the Profile, S1 appendix. Fuller versions of these tables, including medians and
25th = 75th centiles are in S1 and S2 Tables.
Total number of problems found
Site Step 1. Step 2. Step 3. Step 4. Step 5. Step 6.
5: n 8 9 10 9 9 9
Mean [SD] 6.38 [2.00] 6.78 [1.92] 7.50 [2.32] 7.70 [3.65] 7.40 [3.89] 16.50 [6.59]
Full range 5–11 4–11 5–12 1–14 1–16 1–24
4: n 10 10 10 9 9 9
Mean [SD] 9.10 [3.81] 6.20 [2.49] 7.00 [2.63] 4.56 [2.30] 18.33 [7.57] 19.11[6.79]
Full range 2–14 2–10 2–11 2–8 7–27 0–5
3: n 5 5 5 5 5 5
Mean [SD] 8.20 [4.09] 6.60 [2.30] 6.80 [4.32] 10.60 [2.07] 9.40 [1.14] 12.20 [2.39]
Full range 5–15 3–9 1–13 8–13 8–11 9–15
2: n 8 8 8 8 8 8
Mean [SD] 8.13 [3.72] 5.38 [3.58] 15.75 [6.94] 12.75 [5.90] 12.88 [6.31] 14.38 [5.73]
Full range 3–13 1–10 5–28 5–24 5–22 9–28
1: n 10 10 10 10 10 10
Mean [SD] 10.30 [2.21] 17.30 [6.08] 17.30 [6.09] 17.00 [5.25] 16.50 [5.19] 17.10 [4.61]
Full range 7–14 10–25 6–25 6–26 5–23 6–23
doi:10.1371/journal.pone.0140203.t003
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Table 5. Problems addressed with and without the Profile: total numbers and examples. Visits to dentists and opticians were compared ‘before and
after’ (see analysis and Table 6). ADLs—activities of daily living.
Problem Using Proﬁle -124
data collection points
Without the Proﬁle—125
data collection points
Examples of Typical actions
Heart rate 1 1 GP informed
Irregular rhythm 0 0 None when identiﬁed
BP 6 5 Daily recordings. GP informed.
Weight / BMI 19 39 Care plan to encourage/ discourage intake.
Girth 11 0 Care plan for weight loss
Temperature 3 3 Additional blankets offered
oxygen sats 8 0 GP contacted
ECG 0 0 1 recording, no problems
Hand tremor 2 0 Care plans for Parkinson’s and carpal tunnel
Tongue tremor 0 0 No actions
Feet shufﬂing 5 2 Care plans to address risk of falls
Abnormal movements 2 2 Care plans and medication
Posture abnormal 5 5 occupational therapy referral
Gait abnormal on walking 9 11 occupational therapy referral
Balance abnormal/ co-ordination poor &
interferes with ADLs
44 22 Care plans for staff to assist with mobility and
address risk of falling
Bleeding or bruising 12 7 Charting and monitoring. Care plan for polyps.
Feeling the cold 2 0 Extra blankets
Cognitive decline 84 44 Care plans for staff to offer assistance
Convulsions 14 4 Care plan updated. Specialist referral.
Self-harm 2 5 Care plan updated
Violence 17 10 Reports to mental health team
Aggression 49 40 Reported to mental health team, and medication
to be continued.
Irritability 38 2 Care plan to improve explanations. Linked to
constipation and UTI.
Mood ﬂuctuations 45 23 Care plans to reassurance and encourage.
Medication review and changes.
Agitation, anxiety, nervousness 67 52 Care plan to reduce anxiety with music and
reassurance. Medical review.
Behaviour problems e.g. ‘sexualised behaviour’ 35 11 Care plans to offer reassurance. Mental health
review.
Restlessness or pacing 20 4 Mental health team to review patient and /or
medicines.
Hyperactivity 3 2 Care plan modiﬁed.
Panic attacks 2 1 Care plan for management.
Confusion 106 57 Care plan for orientation, GP or mental health
referral. MSU for analysis
apathy, low energy 21 2 Encourage intake. GP review.
Hallucinations, vivid dreams 21 8 Care plan to monitor and reassure. Mental health
review. UTI treatment.
Sleep problems/ insomnia 17 24 Care plan to deal with wakefulness.
Sedation 16 3 GP referral. Omission of mid-day sedation
Diszziness 6 7 Risk of falls assessed. BP monitored.
Falls 32 34 Care plans for assistance, hoists, lighting at night,
mobilising. GP referral.
Headache, migraine 14 0 Analgesia
Tinnitus/hearing problems 9 0 Encouraged to wear hearing aid. Syringing.
(Continued)
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Table 5. (Continued)
Problem Using Proﬁle -124
data collection points
Without the Proﬁle—125
data collection points
Examples of Typical actions
Tingling/pins & needles 0 1 Referred to doctor
Urination 87 84 Continence management. Care plan for retention
management. Medical review.
UTI 28 29 Antibiotics
Reproductive system e.g. polyps, behaviour
change
8 7 GP referral and directed management
Chest pain 2 0 GP referral
Short of breath 5 1 Managed as asthma or chest infection
Hypersalivation/ 5 0 Monitored for chest infection. Hyoscine patch.
Nausea / vomiting 8 0 GP or dietician referral. PRN medicines.
Appetite/ taste changes 10 2 Dietician referral. Care plan for assistance with
feeding.
Bowel control/ diarrhoea 47 59 Care plans for incontinence. Stool charts.
Constipation 13 12 Care plans to monitor. Laxatives.
Rash (+/- itching) 22 21 Creams applied. GP referral.
Swelling/ oedema / pressure areas 20 16 Waterlow scores, GP referral
Sweating / pressure areas 2 0 Enhanced skin care in care plan
Injection site e.g. pain 0 0 No injections
Missing any meals or leaving them unﬁnished
more than once a day
44 19 Care plan to monitor or for soft diet or frequent
small meals or offer alternatives e.g. milk.
Dietician referral.
‘Snacking’ or eating between meals 13 0 Low fat diet.
Drinking 1 pint or more of milk or soya milk per
day. This includes milk added to cereal & hot
drinks
3 0 Milk drinks to be offered between meals. Soya
offered.
Vitamin D intake adequate (time in sunlight, eats
oily ﬁsh)
3 0 Diet updated.
Eating fruit or vegetables every day 4 0 Care plan to encourage
Drinking more than 2 litres, or 6–8 cups, per day.
This includes water, tea, coffee or squash
11 4 Care plan to encourage and monitor
Are drinks sugar free? 4 0 Access to sugar-free drinks
Swallowing difﬁculties 9 8 SALT referral, assistance with eating.
Indigestion or heartburn 3 0 GP referral. Medication.
Problems with teeth or dentures 8 2 Mouth care. Dental referral.
Dry mouth 4 0 Mouth care
Halitosis 1 0 Dental referral
Vision problems or dry eyes 38 20 Optician referral, gel for dry eyes, large print
Is sunscreen available? 0 0 Not used
Is it applied evenly? 0 0 Not used
Dark glasses worn in bright sunlight? 4 0 Available
hair loss 4 0 GP referral for scalp problems
Acne or Herpes simplex reactivation 0 0 Not noted
Any pain? e.g. joint pain, headache 55 24 Care plan to monitor non-verbal clues and pain
charts. Analgesia. Dental referral.
Regular medication taken at the same time each
day
0 0 Not actioned.
More than 2 doses of prescribed medication
missed over any period of seven days in the last
month?
21 1 GP referral. Medicines changed to liquid
formulations.
doi:10.1371/journal.pone.0140203.t005
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b. Benefits. The Profile affected the care of most, but not all, participants. We identified
clinical impact and specific examples, guided by previous work[24]. Some actions related to
direct intervention to manage symptoms, such as referral for GI symptoms (P20, Table 7) or
increased pain relief, whilst others related to health promotion, for example changes to diet
and mouth care. These items were important to address some of the nuanced effects of ADRs.
The intervention increased visits to dentists and opticians. At baseline, 4 had visited dentists
and 27 opticians, within the last 12 months. By the final step, this had increased to 31 and 37,
in association with Profile use (aOR 52.76 [11.80–235.90] and 5.12 [1.45–18.03] respectively).
The importance of this is illustrated by P2 (Table 7).
Eleven participants reported falls in the first step of data collection, and six in the final step.
Profile use did not alter reporting and addressing falls (Table 6), but more care plans were put
in place to address problems with balance (Table 5).
Nurses were more likely to document and treat pain when using the Profile. At baseline, 11/
41 participants had their pain status documented; this increased to 40/41 in the last step. Fewer
participants reported being in pain: 9 and 4 respectively. Without the Profile 1/41 participants
received new analgesia; with the Profile this increased to 9/41, and ranged from transdermal
fentanyl to liquid paracetamol. Use of the Profile increased pain-related documentation and
actions (aOR 3.45 [1.63–7.30] and 3.84 [1.78–8.30] and 1.80–7.78) (Table 6). Similar large
increases in actions taken were seen for problems with balance, cognitive decline, irritability,
mood fluctuations, behaviour problems, restlessness, confusion, apathy, hallucinations, seda-
tion, headache, emesis, missed meals, fluid intake, vision problems, and missed medicines.
There was little change in actions for weight and girth combined, aggression, falls, and inconti-
nence. Other problems were less frequent (Table 5).
The Profile allowed relatively unusual problems to be identified and addressed. Examples
included: a new hearing problem (P9), which resolved on ear syringing; nausea (P12), which
resolved when the daily dose of lactulose was divided; difficulties with urination which triggered
a prescription for tamsulosin (P33); identification of gastro-intestinal ulceration (P20, Table 7).
c. Prescription changes. Neither medication reviews nor documentation of ADRs were
located in patients’ documentation. Introduction of the Profile did not influence the total num-
bers of medicines prescribed, due in part to the increase in analgesia, above, and there was a
small increase over time (Table 8). The baseline differences between the sites did not reach sta-
tistical significance. Although there were no overall changes in total medicines prescribed, the
numbers of participants with any change increased throughout the trial (Table 9).
During the trial there were 18 reductions in mental health medicines affecting 12 service
users: 10 while using the Profile, 1 without the Profile, and 1 both with and without. (Table 7
contains two examples). Reduction in participants’mental health medicines was associated
with Profile use (aOR 4.45 [1.15–17.22]) and the number of prescription medicines at baseline
(aOR 1.17 [1.01–1.35} per medicine) (Table 6).
At baseline, 3/41 participants had sedation levels documented, and recording was complete by
the final step. Three participants had their sedatives reduced (trazodone, lorazepam, risperidone).
d. Functional status and dementia severity. By the end of the study, Bristol ADL scores
and the MOUSEPADmeasure of dementia behavioural and psychological symptoms had dete-
riorated slightly. Changes were not statistically significantly associated with Profile use: Deterio-
ration in dementia severity was associated with antipsychotic prescription at baseline (Table 6).
2. Potential Costs
The direct cost of Profile administration was typically 15–30 minutes time from band 5 nurses,
the starting point for newly registered qualified nurses, an estimated £20.50 ($31.5, €28.2),
Nurse-Led Medicines' Monitoring: A Stepped RCT
PLOSONE | DOI:10.1371/journal.pone.0140203 October 13, 2015 12 / 27
Table 6. Profile Effect on selected outcomes: adjusted analyses. Notes: D = raw, observed (unadjusted) difference in the same units as the variable; β =
β coefficient of profile effect or effect size in the same units as variable; OR = raw (unadjusted odds ratio); aOR = adjusted Odds Ratio, exponent of β.
ADL = activities of daily living. n represents the number of data collection points.
Variable Overall Without
proﬁle
With
proﬁle
Proﬁle Effect 95% CI for
Adjusted
Effect
ICC** Signiﬁcant
covariates
P
values
Adjusted effect,
parameters, β or
aOR (95% CI)
Primary
outcomes
Raw Adjusted* Lower Upper
Total Problems Step 1 0.007 β = 1.82 (0.51–
3.13)
Found Step 4 0.03 β = -1.24 (-2.36–-
0.12)
Mean (sd) 11.52
(6.36)
7.30
(3.18)
15.81
(5.90)
D = 8.51 β = 9.06 7.95 10.16 r = 0.16 Age 0.003 β = 0.16 (0.06–
0.27)
[n] [249] [125] [124] (P<0.001) Number of
medicines
prescribed†
0.003 β = 0.36 (0.13–
0.60)
Total Problems Step 2 <0.001 β = -2.08 (-3.02–
1.14)
Addressed Step 3 0.03 β = -1.04 (-1.96–-
0.12)
Mean (sd) 7.93
(4.23)
6.02
(2.92)
9.86
(4.48)
D = 3.84 β = 3.34 2.57 4.11 r = 0.12 Step 4 <0.001 β = -2.45 (-3.34–
1.52)
[n] [249] [125] [n = 124] (P<0.001) Step 5 <0.001 β = -1.72 (-2.67–
0.77)
Age 0.002 β = 0.14 (0.05–
0.22)
Number of
medicines
prescribed†
0.006 β = 0.26 (0.08–
0.45)
Secondary
outcomes
Mental health
Medicines
Reduction
Proportion (%) 18/208
(8.7%)
3/84
(3.6%)
15/124
(12.1%)
OR = 3.72 aOR = 4.45
(P = 0.03)
1.15 17.22 r = 0.02 Number of
medicines
prescribed†
0.03 aOR = 1.17 (1.01–
1.35)
MOUSEPAD
Mean (sd) 7.53
(6.47)
7.31
(6.90)
7.76
(6.04)
D = 0.45 β = 0.23 -0.47 0.93 r = 0 Antipsychotics at 0.03 β = 4.22 (0.37–
8.07)
[n] [249] [125] [124] (P = 0.52) baseline
Bristol (ADL)
Score
Mean (sd) 30.13
(14.48)
27.81
(14.52)
32.48
(14.11)
D = 4.67 β = 1.37 -0.04 2.78 r = 0.21 None
[n] [249] [125] [124] (P = 0.06)
Examples of
nature of
problems
addressed
Falls Action 66/249 34/125 32/124 OR = 0.94 aOR = 0.73 0.34 1.55 r = 0.01 None
Proportion (%) (26.4%) (27.0%) (25.8%) (P = 0.407)
Falls
Documented
66/249 35/125 31/124 OR = 0.86 aOR = 0.62 0.29 1.32 r = 0 none
Proportion (%) (26.5%) (28.0%) (25.0%) (P = 0.22)
(Continued)
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Table 6. (Continued)
Variable Overall Without
proﬁle
With
proﬁle
Proﬁle Effect 95% CI for
Adjusted
Effect
ICC** Signiﬁcant
covariates
P
values
Adjusted effect,
parameters, β or
aOR (95% CI)
Pain Actions 79/249 24/125 55/124 OR = 3.39 aOR = 3.84 Step 2 0.05 aOR = 0.33 (0.11–
1.00)
Proportion(%) (31.6%) (19.0%) (44.4%) (P = 0.001) 1.78 8.30 r = 0.01 Number of
medicines
prescribed†
0.007 aOR = 1.23 (1.06–
1.43)
Pain
Documented
80/249 25/125 55/124 OR = 3.19 aOR = 3.45 Step 2 0.04 aOR = 0.32 (0.11–
0.96)
Proportion (%) (32.1%) (20.0%) (44.4%) (P = 0.001) 1.63 7.30 r = 0 Number of
medicines
prescribed†
0.005 aOR = 1.23 (1.07–
1.43)
Sedation
Documented
35/249 7/125 28/124 OR = 4.92 aOR = 8.67 Age 0.02 aOR = 1.08 (1.01–
1.16)
Proportion (%) (14.1%) (5.6%) (22.6%) (P<0.001) 2.90 25.86 r = 0.06
Before and after
analyses
Optician Visit 64/82 27/41 37/41 OR = 4.796 aOR = 5.12 1.45 18.03 r = 0 None
Proportion (%) (78.0%) (65.8%) (90.2%) (P = 0.01)
Dentist Visit 35/82 4/41 31/41 OR = 28.67 aOR = 52.76 11.80 235.90 r = 0.122 None
Proportion (%) (42.7%) (9.8%) (75.6%) (P<0.001)
* adjusted for Step, age, number of medicines at baseline, antipsychotics, antiepileptics, antidepressants and SSRIs at baseline;
** ICC, intracluster correlation coefﬁcient, based on raw data;
† number of medicines recorded as prescribed at baseline.
doi:10.1371/journal.pone.0140203.t006
Table 7. Case Reports of benefits of Profile use.
Participant
number
Theme Report
P20 Investigating poor
intake
A lady in her mid 90s with a diagnosis of mild to moderate dementia was prescribed: ranitidine, aspirin,
furosemide, simvastatin, levothyroxine, zopiclone, ramipril, sodium valproate as Epilim1. On the second use
of the Proﬁle, abdominal pain was identiﬁed as a possible cause of irregular dietary/ food intake. This was
followed up with the GP, and the participant was investigated for gastro-intestinal ulceration.
P2 Investigating poor
intake
A gentleman of in his mid 70s with a diagnosis of Alzheimer’s disease, ischaemic heart disease, and arthritis
had no record of problems with dietary intake or dentists’ visits before the Proﬁle was introduced. On ﬁrst use,
the Proﬁle identiﬁed dental problems, poor intake and missed or unﬁnished meals. A dental appointment was
then arranged, and the dentist needed to extract a decayed tooth. On subsequent assessments, meals were
no longer missed, fruit and milk intake had improved and sugary drinks were no longer used.
P19 Recognising ADRs A lady in her late 80s with a diagnosis of Alzheimer’s disease was prescribed mirtazapine, lactulose, senna,
diazepam, aspirin, omeprazole, folic acid, alendronic acid, vitamin D supplements as Calcichew D3 forte1,
simvastatin, and risperidone as needed. Initial monitoring (Step 4) indicated several problems including:
cognitive decline, violence, aggression, agitation, hallucinations, risk of falls, problems with dentures, and
pain. The nursing team were proactive in discontinuing risperidone, and violence, aggression, agitation,
hallucinations, falls, denture problems and pain resolved. One month later, the potential problem of falls was
incorporated into the personalised care plans for the ﬁrst time, triggering discontinuation of diazepam.
P16 Recognising ADRs A lady in her late 80s, diagnosed with dementia was prescribed hyoscine as needed, oxazepam,
carbamazepine, omeprazole, levomepromazine, senna, magnesium hydroxide, and paracetamol. At ﬁrst
administration of the Proﬁle (Step 3), she was noted to be aggressive, restless, confused, sedated and
agitated. In accordance with Proﬁle guidelines, hyoscine had been discontinued by Step 4. By the end of the
study, aggression, restlessness and sedation were no longer recorded as problematic. The potential for falls
was recorded on the Proﬁle, but not elsewhere in the records.
doi:10.1371/journal.pone.0140203.t007
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based on salary costs of £41 per hour[69]. Some nurses needed an hour to read through the
guidelines carefully before first administration, and administration times ranged 10–60 min-
utes, costing £7–41 ($10.8–63.0, €9.6–56.4). Administration times were shorter when nurses
had familiarised themselves with the appended guidelines. Addressing problems or care deficits
identified by the Profile entailed indirect costs: for example, referrals and visits to opticians and
dentist increased in association with the intervention. A visit to the community dentist is esti-
mated to cost £115 ($176.7, €158.2) and an optician £21 ($32.3, €28.9)[70]. Some prescribing
changed, but no changes in high cost medicines were observed.
Potential savings were identified. Improved vision, following opticians’ input, combined
with reduction of medicines such as diazepam and antipsychotics, which are associated with
dizziness, falls and fractures[60,71], could lead to savings by reducing falls. The costs of pain,
Table 8. Number of prescribed medicines in each step for each site. Bold text indicates roll-out of medicines’monitoring and Profile administration 1
month before these data collection points (occasions when researchers extracted data from participants’ records). n = number of service users in the site.
One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised between steps 3 & 4. Participants joined site 5 at
steps 2 and 3. Problems explored are listed in Table 5 and on the Profile, S1 Appendix. Fuller versions of these tables, including medians and 25th = 75th cen-
tiles are in S3 table.
Number of prescribed medicines
Site Step 1. Step 2. Step 3. Step 4. Step 5. Step 6.
5: Sum (n) 85 (8) 96 (9) 109 (10) 105 (9) 108 (9) 115 (9)
Mean [SD] 10.63[3.07] 10.67 [3.16] 10.90 [3.28] 11.67 [2.92] 12.00 [3.12] 12.78[40.6]
Full range 7–15 7–16 6–16 6–15 7–16 6–19
4: Sum (n) 91 (10) 93 (10) 18 (10) 92 (9) 98 (9) 101 (9)
Mean [SD] 9.10 [4.23] 9.30 [4.24] 9.60 [3.95] 10.22 [4.30] 10.89 [4.83] 11.22 [4.06]
Full range 4–18 4–18 5–18 5–19 6–21 7–18
3: Sum (n) 48 (5) 50 (5) 49 (5) 50 (5) 49 (5) 49 (5)
Mean [SD] 9.60 [1.14] 10.00 [2.00] 9.80 [1.79] 10.00 [1.23] 9.80 [1.30] 9.80 [1.30]
Full range 8–11 8–12 8–12 8–11 8–11 8–11
2: Sum (n) 89 (8) 89 (8) 89 (8) 88 (8) 85 (8) 89 (8)
Mean [SD] 11.13 [3.91] 11.13 [4.29] 11.13 [3.56] 11.00 [3.21] 10.63 [3.29] 11.13 [3.56]
Full range 6–19 6–20 6–18 6–17 6–17 6–18
1: Sum (n) 68 (10) 72 (10) 72 (10) 71 (10) 70 (10) 84 (10)
Mean [SD] 6.80 [3.36] 7.20 [3.33] 7.20 [3.49] 7.10 [3.35] 7.00 [3.50] 8.40 [3.98]
Full range 2–13 2–13 2–13 2–13 2–14 2–14
doi:10.1371/journal.pone.0140203.t008
Table 9. Numbers of participants with any changemade to any of their prescribed medications at each step in each site. Bold text indicates roll-out
of medicines’monitoring and Profile administration 1 month before these data collection points (occasions when researchers extracted data from participants’
records). n = number of service users in the site. One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised
between steps 3 & 4. Participants joined site 5 at steps 2 and 3. Problems explored are listed in Table 5 and on the Profile, S1 Appendix. Fuller versions of
these tables, including medians and 25th = 75th centiles are in S3 Table.
Site Number with changes to prescribed medicines
Step 1. Step 2. Step 3. Step 4. Step 5. Step 6.
5: n/N (%) NA 1/9 (11%) 1/10 (10%) 7/9 (78%) 7/9 (78%) 6/9 (67%)
4: n/N (%) NA 3/10 (30%) 5/10 (50%) 6/9 (67%) 7/9 (78%) 8/9 (89%)
3: n/N (%) NA 1/5 (20%) 1/5 (20%) 3/5 (60%) 1/5 (20%) 4/5 (80%)
2: n/N (%) NA 2/8(25%) 5/8 (63%) 6/8 (75%) 4/8 (50%) 5/8 (63%)
1: n/N (%) NA 1/10 (10%) 4/10 (40%) 3/10 (30%) 4/10 (40%) 6/10 (60%)
doi:10.1371/journal.pone.0140203.t009
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sedation, poor oral hygiene and poor eyesight, and their amelioration, are hard to quantify, but
may affect Health Related Quality of Life.
3. Harms
Implementation of the WWADR Profile was neither observed nor reported to be directly
harmful, and Bristol ADL and MOUSEPAD scores did not deteriorate significantly. The
research entailed no more than minimal risk, defined as clinical examination and record
review[66]: the Profile has been freely available in the public domain since 2004[42], and all
questions and observations are of a nature that should be pursued under routine care. The time
taken identifying and responding to problems may have distracted nurses from other tasks, but
prioritisation of actions was at the discretion of the multidisciplinary team. Medicines were
changed in response to needs identified. Neither participants nor their families reported nega-
tively on the amount of time spent in completing the WWADR Profile. At recruitment, pres-
sure of existing work was cited by nurse managers, acting as gatekeepers, as their reason for
non-participation; without further information from sites not involved, it is difficult to explore
how this might relate to the 30 minutes needed to administer the Profile.
Discussion
To our knowledge, no previous trials have tested nurse-led medicines’monitoring interven-
tions in a cohort stepped wedge cluster RCT. Our intervention increased the numbers of prob-
lems identified and addressed, improved pain management, and reduced prescriptions of
mental health medicines. We identified potential to augment quality and safety of care and
reduce costs.
Strengths and Limitations
Generalisability of findings is supported by consistency across the majority of trial sites, low
attrition, and with earlier work[22–25], with the caveats that those too ill to undergo measure-
ments of vital signs were excluded, and all sites had pre-existing contact with the University
and were in an area of the European Union (EU) where GDP is 75% below the community
average[72]. The site (3) with the lowest recruitment and oldest participants (Table 1)
addressed fewer problems but changed more medicines than others (Tables 4 and 9), and com-
pletion of some items relied on nurses’ intimate knowledge of participants who lacked the cog-
nitive ability to understand questions, suggesting that clinical gains may vary between settings.
International transferability of findings rests with readers’ interpretations. Prescribing patterns,
including number of medicines prescribed (median 9, range 2–19) reflects previous reports
[73]. The 50% recruitment rate for sites warrants cautious generalisation of findings to care
homes feeling too pressurised to participate in research. Any association with nurses’ self-
reported lack of confidence in medicines’management[74] or the requirement for the Profile
to be administered is uncertain. Volunteer[75] and selection[76] bias within sites was mini-
mised by the high participation rate. This was attributed to the REC’s support for witnessed
verbal assent to participation, in accordance with the Ottawa statement[66], to avoid overbur-
dening participants’ relatives, many of whom were frail and elderly[42].
Nursing work that is unrecorded is regarded as incomplete or ‘not done’[77]. However,
some observations and actions, particularly vital signs (Table 2), were incompletely docu-
mented, despite the known risk of hypotension associated with antipsychotics[78] and antide-
pressants[34]., and communications’ systems did not facilitate transfer of laboratory results.
However, care homes’ records are regularly inspected by licensing authorities (CSSIW), ensur-
ing that all medicines administered are fully and accurately recorded. We think it unlikely that
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social desirability responses or the Hawthorne[79] effect would have affected nurses’ comple-
tion of documentation unevenly across trial sites and steps.
We acknowledge the potential for “exposure suspicion bias” [80:55] to increase the num-
bers of problems recorded. Conversely, some problems, such as poor balance or gait may be
overlooked or accepted as integral to participants’ conditions. Such “entrapment by prior
expectations” [81:38] may affect profiling of ADRs[42], but is likely to have been consistent
throughout the trial. We anticipated some fluctuations in recording over time, because signs
and symptoms change. For example, bruises appear, eating patterns alter, and if people become
dehydrated, due to changes in temperature, intake or infection, drug elimination decreases,
worsening any ADRs.
Blinding during administration, data capture and outcome assessment in non-pharmaco-
logical[82], cluster[48] or pragmatic trials may be impossible[83], increasing risk of bias[84], in
line with observers’ expectations[85]. Nurses and some, but not all, participants were aware of
administration of the Profile. The presence of the Profiles in the notes precluded blinding dur-
ing data collection, and the obvious increase in problem detection with the Profile (Table 3)
was apparent to data analysts. Detection bias of outcomes was minimised, but not removed, by
a pre-arranged data collection template and the low subjectivity of outcome data extracted
from standardised documentation, such as medicines’ administration records or nutrition
assessments[86]. Systematic review indicates that some 3% unblinded assessments are likely to
be misclassified[87], which would not materially affect interpretation of our findings.
Contamination by subconscious transfer of aspects of an intervention to controls may
dilute its effects[88]. Introduction of the study before implementation may have sensitised staff
to medicines’management, and medicine changes increased before use of the Profile in sites 4
& 5 (Table 6). The sites were unlikely to have discussed the trial as they were geographically
dispersed and all nurses worked at only one site.
Global outcome measuresmay be better suited to population comparisons than clinical tri-
als, as they appear to be insufficiently sensitive to prescription changes[19,89], and subtle but
important improvements, such as increased oral hygiene and analgesia. Therefore, interven-
tions to optimize prescribing, identification and resolution of medication-related problems or
pain may not influence scores on global outcome measures[19,57,90–94]. While nurse-led and
pharmacist-led interventions improve prescribing[95,96], mainly in patients not receiving spe-
cialist care[27], they may not change global outcome measures[19,41,89,97–99]. Although care
improved, for example by reducing prescribing of sedatives and increasing administration of
analgesia, global measures did not. Scores for activity of daily living (Bristol ADL) and psycho-
pathology (MOUSEPAD) remained unchanged; however, participants were suffering from
dementia, which would normally deteriorate over 5–6 months. The ambivalence between
auditable processes of care, such as medication administration[3,4] and global outcomes, such
as levels of functioning, reflects the inconsistency in the links between the processes and out-
comes of care.
The risks ofmultiple testing were balanced against the benefits of formalising the signifi-
cance of observed differences. We did not apply statistical tests to all items that could have
been actioned, and the observed differences (Table 5) should be considered together with the
formal analyses presented in Table 6.
Addressing the ADR Problem
1. Clinical gains. Dose titration for people with dementia is challenging: medicating the
neuropsychiatric symptoms of dementia is of uncertain benefit[61,100–103], and antipsychot-
ics are not recommended unless other measures have failed and then only for short-term
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administration[104]. Routine administration of a structured, standardised instrument was a
low risk strategy to facilitate medication titration and compensate for any under-ascertainment
of ADRs or under-treatment due to patients’ impaired communication. It was also successful
in enhancing care planning to address nursing needs, such as poor fluid intake, missed meals
and behaviour problems[3,4] (Tables 2 and 5).
Some 15% of older adults in the UK are prescribed at least 1 potentially inappropriate medi-
cine[105], and medicines’management is crucial to the optimisation of long-term conditions
and avoidance of harm. However, many ADRs are subtle and ill-defined, and signs and symp-
toms, such as cognitive impairment[61] or impaired continence[106], may resemble pre-exist-
ing conditions or ageing or dehydration. Their aetiology is often multifactorial or uncertain[7]:
for example, cognitive impairment may reduce fluid intake[3,4,107], exacerbating urinary
symptoms and constipation[108], which are also ADRs to antidepressants, benzodiazepines
and antipsychotics[52,34]. Determination of aetiology for each problem or assessment of
appropriateness of prescribing is outside the remit of the Profile. For example: xerostomia war-
rants nursing or dental interventions whether due to dehydration, antipsychotics, SSRIs,
AEDs, benzodiazepines or anti-muscarinics; similarly, confusion should be brought to the
attention of prescribers whether due to dementia, or caused or exacerbated by cardiovascular
agents, antipsychotics, SSRIs, AEDs, benzodiazepines or anti-muscarinics[34,52,53,61]. Rather,
by addressing the diverse problems vulnerable to exacerbation by prescribed medicines
[52,109], the Profile works towards incremental optimisation of health. In view of the paucity
of the evidence base on potential adverse drug reactions[110–112], to optimise clinical gain,
the Profile makes a thorough and detailed check for potential medication-related harms, risk-
ing over-ascertainment, rather than overlooking potentially treatable problems of equivocal
aetiology. Interpretation of such inclusivity rests with readers. The diversity of problems identi-
fied and addressed suggests there may be some merit in compiling a single Profile of problems
ahead of physician or pharmacist review.
Previously, introduction of nurse-led medicines’monitoring expedited the recognition and
treatment of unsuspected problems, such as orthostatic hypotension, coupled beats, hyperten-
sion, constipation, and inadequate diet[22,23], need for medication review, immunisations
[25], suboptimal oral care, pain and sedation[24]. Including a question on pain in a compre-
hensive profile improved pain management, as did administration of purposive instruments
[57,113]. Similarly, pharmacist-led medicines’ review yielded greater clinical gains by treating
previously unrecognised symptoms than discontinuing inappropriate medicines[114].
2. Costs. Additional healthcare needs emanating from medicines’mismanagement cost
the USA $213bn (8% of total healthcare spend) in 2012, mainly due to an additional 10m hos-
pitalisations[115]. Inappropriate prescribing to those aged70 in Northern Ireland in 2009/
2010 cost €6,098,419, 5.38% of overall pharmaceutical expenditure[116]. Pharmacist review
made a non-significant difference to nursing home residents’ healthcare costs[117], and was
ineffective in older people in the community[90]. Our Profile was easy to administer and
addressed the problems of incomplete documentation (Table 1), non-adherence (Tables 2 and
5), errors, inappropriate prescribing (Tables 6 and 9) and mismanagement cheaply (~£20). The
Profile increased nurses’ workloads: not only was time needed for completion with partici-
pants, but also for contacting prescribers, reviewing care plans, arranging GP, dental and opti-
cian appointments, to the benefit of participants. Whilst the results of the monitoring affected
prescribing and referrals, this was within the context of standard NHS care, and these addi-
tional NHS costs were not direct results of the monitoring. We did not have the resources to
estimate the costs or savings for each participant.
3. Harms. Medicines’monitoring and review are reported not to cause harm[19,92,93],
and the additional care plans and referrals reported had no risk attached (Table 5). Profiles
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should neither duplicate existing documentation nor increase professionals’ bureaucratic bur-
den[118], but there is merit in a single instrument to identify, communicate and address prob-
lems. Where nurses undertake tasks outside traditional nursing roles, time and educational
preparation[74] are perceived barriers. Any change needs to be seen as beneficial, resourced
and achievable[6]. To allay concerns regarding the necessary investment in time and learning,
the clinical effectiveness of ADR profiles in identifying and ameliorating the burdens of treat-
ment should be demonstrated[119].
A Strategy worth exploring. Neither guidelines[15,35,43] nor literature reviews[6] offer
consensus or structures for identifying and addressing medicine-related harm and adverse
events. Further research into increased nursing vigilance and improved systems for actively
monitoring patients for known adverse effects of prescribed medicines is warranted[20,120–
122], and monitoring profiles are ideal[123] (Fig 2). Profiles do not replace clinical knowledge
and experience: they juxtapose information on signs and symptoms with therapeutic regimens
in a succinct, formal assessment, and suggest solutions to problems potentially related to pre-
scribed medicines[124]. Our Profile augments professionals’ and patients’ awareness of ADRs
[125], and would mitigate public bodies’ concerns over iatrogenesis[1,2,112,126] and under-
reporting of ADRs[127,128]. Adoption would expedite: pain management[662,124], proactive
and prompt sharing of complete prescribing information during patient transfer[35:77], and
recommendations from inquiries into health care failings. These include: enhanced transpar-
ency; inter-disciplinary teamwork[4]; informing patients of their medicines’ adverse effects
[3:418]; easily accessible and systematic recording of routine observations[3:129]; frequent
checking to minimize medication errors[3:1613]; a “zero tolerance” approach to the improper
administration of sedation and medicines[3:111,4:34]; comprehensive education initiatives in
medication management[4:R8]; monitoring food and fluid intake[3:111,4:R4].
Conclusion
Nurse-led medicines’monitoring improved some aspects of care, including prescribing and
pain management, and focused attention on participants’ reports of adverse events[99,129].
The intervention is feasible[24], low cost, low risk and, when operationalized, convenient for
service users and professionals, and offers potential for cost savings and increased quality and
safety of care. However, larger, multicentre trials are needed to examine long-term effects of
structured medicines’monitoring on clinical outcomes[130], nurses’ workloads, and bridging
the gap between patients and prescribers (Fig 2)[20,120–122].
Fig 2. Themedication chain.
doi:10.1371/journal.pone.0140203.g002
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